• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day

    7/30/24 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    • Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM® Day on August 21, 2024
    • Members receive an exclusive gift card offer and a chance to win $10,000*

    IRVINE, Calif., July 30, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 21. After a successful first year, JUVÉDERM® Day is back with limited time offers, savings, and exclusive deals through Allē, the Allergan Aesthetics loyalty rewards program.

    "JUVÉDERM® Day 2023 logged the most treatments in a single day for the brand, and our goal is to surpass that this year. During this year's event, we are providing even more exclusive offers to drive consumers into practices," said Jasson Gilmore, Senior Vice President U.S. Aesthetics. "Now is the perfect time for consumers to speak with their aesthetic specialist about treatment with products in the JUVÉDERM® Collection of Fillers to achieve smooth, natural-looking, and long-lasting results."

    More than 18 million consumers are interested in receiving treatment with dermal filler, and JUVÉDERM® offers a robust collection of products specifically designed to address consumers' top aesthetic concerns. JUVÉDERM® remains the number one chosen hyaluronic acid (HA) dermal filler collection on the market and is trusted by providers globally1.

    Consumers eager to try treatment and participate in JUVÉDERM® Day are encouraged to join Allē at alle.com/registration to receive exclusive offers, including:

    • BOGO Gift Cards†: On Wednesday, August 21 starting at 9 a.m. Pacific Time, Allē Members who purchase a $75 JUVÉDERM® gift card at JuvedermDay.com will receive an additional $75 JUVÉDERM® gift card for free, while supplies last. Terms and conditions apply.
    • Book a Consultation, Save with Allē Flash: Schedule a consultation with a participating Allē provider between August 21 and September 30, and check in with Allē Flash for a chance to instantly save up to $500 on your JUVÉDERM® treatment.
    • JUVÉDERM® Day Sweepstakes: Get treated by September 30 and enter the JUVÉDERM® Day Sweepstakes for a chance to win $10,000*.

    "As we continue to see consumer trends shift towards a more natural-looking aesthetic, my patients are coming to me specifically looking for subtle treatment outcomes, and I trust the JUVÉDERM® Collection of Fillers to help me deliver the results they desire," said Dr. Deborah Sherman, Board-certified ophthalmologist, Fellowship-trained Oculofacial Plastic Surgeon, and founder of Sherman Aesthetic Center in Nashville, Tenn. "The JUVÉDERM® Day celebration provides a great opportunity to spark new conversations around my patients' aesthetic goals."

    JUVÉDERM® Day is recognized by National Day Archives as an official holiday on the National Day Registry™, JUVÉDERM® Day will be held annually on the third Wednesday of August. For more information on the JUVÉDERM® Collection of Fillers, visit Juvederm.com and follow @JUVEDERM on Instagram and TikTok.

    In serving more than seven million Members across ~30,000 practices to date, part of Allē's mission is to help educate consumers about aesthetic treatments, and to simplify office operations for practices. From its inception, Allē has disrupted the aesthetics industry by offering the most robust rewards program. Allē is the first and only loyalty program in the aesthetics market to also offer consumers the ability to earn points on over 50 non-Allergan Aesthetics treatments and brands. By providing Members with information, tools, and incentives, and now with flexible ways to pay though Allē Payment Plans, Allē empowers consumers along their treatment journey, making the next product purchase or treatment closer within reach.

    *NO PURCHASE NECESSARY TO ENTER TO WIN. Open to Allē Members in 50 U.S./D.C.; 18+ (19+ in AL, NE, 21+ in MS) Void where prohibited. Registration starts 08/21/2024. See full Official Rules for all details and how to enter without purchase at 

    https://alle.com/lp/juvdaysweeps-official-rules.

    †Gift cards can be used exclusively towards treatment with any product in the JUVÉDERM® Collection of Fillers. SKINVIVE by JUVÉDERM® is excluded from all promotions.

    About Allergan Aesthetics

    At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

    JUVÉDERM® Injectable Gel Fillers Important Information

    APPROVED USES

    JUVÉDERM® VOLUX® XC injectable gel is for deep injection to improve moderate to severe loss of jawline definition in adults over the age of 212.

    JUVÉDERM® VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss and for augmentation of the chin region to improve the chin profile in adults over 213.

    JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC injectable gels are for injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds 4–6. JUVÉDERM® VOLLURE® XC injectable gel is for adults over 214.

    JUVÉDERM® Ultra XC injectable gel is also for injection into the lips and perioral area for lip augmentation in adults over 215.

    JUVÉDERM® VOLBELLA® XC injectable gel is for injection into the lips for lip augmentation and correction of perioral lines, and for injection into the undereye hollows to improve the appearance of undereye hollows in adults over the age of 217.

    IMPORTANT SAFETY INFORMATION

    Are there any reasons why I should not receive any JUVÉDERM® formulation?

    Do not use these products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), if you are allergic to lidocaine or the Gram-positive bacterial proteins used in these products, or if you have had previous allergic reactions to hyaluronic acid fillers.

    What warnings should my doctor advise me about?

    • One of the risks with using dermal fillers is the unintentional injection into a blood vessel. The chances of this happening are very small, but if it does happen, the complications can be serious and may be permanent. These complications, which have been reported for facial injections, can include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. Most of these events are irreversible.
    • If you have changes in your vision, signs of a stroke (including sudden difficulty speaking, numbness or weakness in your face, arms or legs, difficulty walking, face drooping, severe headache, dizziness, or confusion), white appearance of the skin, or unusual pain during or shortly after treatment, you should notify your health care practitioner immediately.
    • The use of dermal fillers where skin sores, pimples, rashes, hives, cysts, or infections are present should be postponed, as this may delay healing or make skin problems worse.
    • The effectiveness of removal of any dermal filler has not been studied.

    What precautions should my doctor advise me about?

    • JUVÉDERM® VOLBELLA® XC should only be injected into undereye hollows by doctors who have completed the necessary training for this treatment area. To find a doctor, visit Juvederm.com/find-a-specialist. Doctors who complete the training will be listed with a symbol
    • The safety of these products for use during pregnancy or while breastfeeding has not been studied
    • The safety of JUVÉDERM® VOLUMA® XC has not been studied in patients under 35 years or over 65 years for cheek augmentation, or under 22 years and over 80 years for chin augmentation. The safety of JUVÉDERM® VOLUX® XC, JUVÉDERM® VOLLURE® XC and JUVÉDERM® VOLBELLA® XC has not been studied in patients under 22 years, and the safety of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC has not been studied in patients under 18 years
    • The safety and effectiveness of treatment with JUVÉDERM® products in anatomical regions outside of their approved uses have not been established in clinical studies
    • If you have a history of excessive scarring (thick, hard scars) or pigmentation disorders, treatment in these patients has not been studied and may result in additional scars or changes in pigmentation
    • If you are planning other procedures including laser treatments or a chemical peel, there is a possible risk of inflammation at the treatment site if these procedures are performed closely before or after JUVÉDERM® injectable gel treatment
    • Tell your doctor if you are on therapy used to reduce your body's natural defense system (such as steroids, chemotherapy, and medicines to treat autoimmune diseases, HIV, and AIDs), as these may increase your risk of infection; and medications that can prolong bleeding (such as aspirin, ibuprofen, or other blood thinners), as these may result in increased bruising or bleeding at the injection site.
    • Avoid applying makeup for 12 hours after treatment and minimize strenuous exercise, exposure to extensive sun or heat, and alcoholic beverages within the first 24 hours following treatment, as these may cause temporary redness, swelling, and/or itching at the injection site
    • JUVÉDERM® VOLUMA® XC was not studied in patients with significant loose skin of the chin, neck, or jaw
    • The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
    • Patients who experience skin injury near the site of JUVÉDERM® VOLUMA® XC injection may be at a higher risk for adverse events
    • Tell your doctor if you have already been injected with dermal fillers in the same area as the one(s) you are about to be treated for. This information helps your doctor decide when and whether you should get treatment

    What are possible side effects of treatment?

    The most commonly reported side effects with JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported.

    These side effects are consistent with other facial injection procedures and most will resolve within 30 days. Your doctor may choose to treat side effects persisting longer with antibiotics, steroids, or hyaluronidase (an enzyme that breaks down hyaluronic acid).

    As with all skin injection procedures, there is a risk of infection.

    To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372. Please also visit Juvederm.com or talk to your doctor for more information.

    Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

    References:

    1. Data on File, Allergan; Dermal Filler AMT, November 2023.
    2. JUVÉDERM® VOLUX® XC Directions for Use, 2023.
    3. JUVÉDERM® VOLUMA® XC Directions for Use, 2023.
    4. JUVÉDERM® VOLLURE® XC Directions for Use, 2023.
    5. JUVÉDERM® Ultra XC Directions for Use, 2023.
    6. JUVÉDERM® Ultra Plus XC Directions for Use, 2023.
    7. JUVÉDERM® VOLBELLA® XC Directions for Use, 2023.

    © 2024 AbbVie. All rights reserved. JUVÉDERM and its designs are trademarks of Allergan Holdings France SAS, and AbbVie company, or its affiliates. All other trademarks are property of their respective owners.

     

    Cision View original content:https://www.prnewswire.com/news-releases/allergan-aesthetics-celebrates-the-second-annual-juvederm-day-302209123.html

    SOURCE AbbVie

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    4/30/2026$234.00Neutral → Buy
    BofA Securities
    4/21/2026$262.00Buy
    Canaccord Genuity
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    2/20/2026$275.00Overweight
    Barclays
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    1/7/2026$240.00Neutral
    UBS
    12/10/2025$265.00Hold → Buy
    HSBC Securities
    11/13/2025$280.00Sector Outperform
    Scotiabank
    More analyst ratings

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-16) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/26/2026. Application Category: BLA, Application Number: 761262, Application Classification:

    6/29/26 4:48:07 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-45) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/26/2026. Application Category: BLA, Application Number: 761105, Application Classification:

    6/29/26 4:48:07 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-44) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/12/2026. Application Category: BLA, Application Number: 761105, Application Classification:

    6/16/26 4:45:14 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

    Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeksBoey® offers a differentiated treatment option for many people who are curious about facial injectables²NORTH CHICAGO, Ill., July 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced the European Commission has approved Boey® (trenibotulinumtoxinE) in Europe, for the temporary improvement in the appearance of moderate to severe lines between the eyebrows

    7/17/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

    SkinMedica® launches Regenerative Science Advisory Board to shape future innovationExpands its state-of-the-art research and development (R&D) facility to support the next generation of science-led innovationDebuts flagship retail experiences designed to support practice and patients' needs IRVINE, Calif., July 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE:ABBV) company, is proud to announce SkinMedica's expanded commitment to regenerative science, advancing investments that will support innovation, research, clinical insight, and patient experience. "Stemming from its origins in wound-healing research, SkinMedica was founded on the principles of regenerative skincare," said

    7/14/26 8:05:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics

    Issued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pillars, facial, body, and mechanical performance, as it advances a single-formulation regenerative platform toward a predicate-based 510(k).USA News Group News CommentaryRENO, Nev. , July 9, 2026 /CNW/ -- In regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one problem. That is the framing behind a milestone from Conexeu Sciences Inc. (NASDAQ:CNXU), a preclinical-stage regenerative tissue company that has completed the P

    7/9/26 8:16:00 AM ET
    $EOLS
    $ABBV
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AbbVie upgraded by BofA Securities with a new price target

    BofA Securities upgraded AbbVie from Neutral to Buy and set a new price target of $234.00

    4/30/26 7:15:05 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on AbbVie with a new price target

    Canaccord Genuity initiated coverage of AbbVie with a rating of Buy and set a new price target of $262.00

    4/21/26 7:30:27 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on AbbVie with a new price target

    RBC Capital Mkts initiated coverage of AbbVie with a rating of Outperform and set a new price target of $260.00

    2/25/26 7:48:26 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    SEC Filings

    View All

    AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    7/6/26 4:12:09 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by AbbVie Inc.

    11-K - AbbVie Inc. (0001551152) (Filer)

    6/24/26 5:26:44 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AbbVie Inc. (0001551152) (Filer)

    6/22/26 7:11:21 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Rapp Edward J

    4 - AbbVie Inc. (0001551152) (Issuer)

    7/2/26 5:00:14 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Quaggin Susan E

    4 - AbbVie Inc. (0001551152) (Issuer)

    7/2/26 5:00:12 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Falk Thomas J was granted 1,118 shares, increasing direct ownership by 93% to 2,321 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    5/12/26 5:00:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    1/25/24 4:59:27 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    SC 13G/A - AbbVie Inc. (0001551152) (Subject)

    2/9/23 10:54:46 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Financials

    Live finance-specific insights

    View All

    AbbVie to Host Second-Quarter 2026 Earnings Conference Call

    NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas incl

    6/26/26 8:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

    Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseasesApogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitisApogee's pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthmaApogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billionAbbVie

    6/22/26 7:00:00 AM ET
    $ABBV
    $APGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., June 18, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable August 14, 2026, to stockholders of record at the close of business on July 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges

    6/18/26 4:05:00 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    View All

    AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

    Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

    2/14/25 7:40:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)